Literature DB >> 4118161

Lipid absorption, bile acids, and cholesterol metabolism in patients with chronic liver disease.

T A Miettinen.   

Abstract

Faecal bile acids and neutral sterols of cholesterol origin were decreased in patients with chronic liver disease, while urinary bile acids were constantly, but never greatly, increased. Thus, production of cholesterol and its conversion to bile acids was decreased in these patients. Faecal fat was only slightly increased, even in cases with a very low bile salt output, but it was negatively correlated with faecal bile acids. The reduced capacity of these patients to synthesize bile acids was shown by the fact that cholestyramine treatment, although it decreased urinary bile acids, increased faecal bile acids only slightly. The resin constantly increased faecal neutral sterols, while the increase of faecal fat was insignificant. Thus, the absorption of fats, as compared with that of sterols, was less strongly reduced by interruption of the enterohepatic circulation of bile salts. In one cirrhotic patient markedly increased faecal bile acids apparently caused cholerrhoeic diarrhoea, which was easily controlled with cholestyramine. The latter consistently increased elimination of cholesterol in cirrhotic patients, but serum cholesterol was not consistently decreased, and in these patients, in contrast to the control subjects, it was difficult to detect changes in cholesterol synthesis with the acetate-mevalonate test and serum methyl sterols.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4118161      PMCID: PMC1412370          DOI: 10.1136/gut.13.9.682

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

Review 1.  Liver disease and malabsorption.

Authors:  M S Losowsky; B E Walker
Journal:  Gastroenterology       Date:  1969-03       Impact factor: 22.682

2.  Urinary excretion of bile acids in patients with obstructive jaundice and hepatocellular disease.

Authors:  J A Gregg
Journal:  Am J Clin Pathol       Date:  1968-03       Impact factor: 2.493

3.  Gas-liquid chromatographic and mass spectrometric studies on sterols in vernix caseosa, amniotic fluid and meconium.

Authors:  T A Miettinen; T Luukkainen
Journal:  Acta Chem Scand       Date:  1968

4.  The formation of bile acid sulfates: a new pathway of bile acid metabolism in humans.

Authors:  R H Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

5.  The mechanism of fat absorption in the bile fistula rat.

Authors:  R G Morgan; B Borgström
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1969-04

6.  The metabolism of intravenously injected isotopic cholic acid in Laennec's cirrhosis.

Authors:  M Blum; N Spritz
Journal:  J Clin Invest       Date:  1966-02       Impact factor: 14.808

7.  A physicochemical approach to the intraluminal phase of fat absorption.

Authors:  A F Hofmann
Journal:  Gastroenterology       Date:  1966-01       Impact factor: 22.682

8.  Bile salt secretion in cirrhosis of the liver.

Authors:  L A Turnberg; G Grahame
Journal:  Gut       Date:  1970-02       Impact factor: 23.059

9.  Dietary beta-sitosterol as an internal standard to correct for cholesterol losses in sterol balance studies.

Authors:  S M Grundy; E H Ahrens; G Salen
Journal:  J Lipid Res       Date:  1968-05       Impact factor: 5.922

10.  Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea.

Authors:  W E Meihoff; F Kern
Journal:  J Clin Invest       Date:  1968-02       Impact factor: 14.808

View more
  16 in total

1.  Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.

Authors:  M Allocca; A Crosignani; A Gritti; G Ghilardi; D Gobatti; D Caruso; M Zuin; M Podda; P M Battezzati
Journal:  Gut       Date:  2006-04-21       Impact factor: 23.059

2.  Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.

Authors:  Haifeng Lu; Zhongwen Wu; Wei Xu; Jiezuan Yang; Yunbo Chen; Lanjuan Li
Journal:  Microb Ecol       Date:  2011-02-01       Impact factor: 4.552

Review 3.  Gut microbiota and liver diseases.

Authors:  Masami Minemura; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

4.  Dietary Polysaccharides in the Amelioration of Gut Microbiome Dysbiosis and Metabolic Diseases.

Authors:  Shokouh Ahmadi; Rabina Mainali; Ravinder Nagpal; Mahmoud Sheikh-Zeinoddin; Sabihe Soleimanian-Zad; Shaohua Wang; Gagan Deep; Santosh Kumar Mishra; Hariom Yadav
Journal:  Obes Control Ther       Date:  2017-12-18

5.  Hyperlipidemia in Chronic Cholestatic Liver Disease.

Authors:  Matteo Longo; Andrea Crosignani; Mauro Podda
Journal:  Curr Treat Options Gastroenterol       Date:  2001-04

6.  Biliary squalene levels in hepatobiliary disease.

Authors:  Y Nosaka; Y Yamanishi; C Hirayama
Journal:  Gastroenterol Jpn       Date:  1985-08

7.  Altered bile acid metabolism in primary biliary cirrhosis.

Authors:  R Raedsch; B H Lauterburg; A F Hofmann
Journal:  Dig Dis Sci       Date:  1981-05       Impact factor: 3.199

8.  Contribution of gut bacteria to liver pathobiology.

Authors:  Gakuhei Son; Michael Kremer; Ian N Hines
Journal:  Gastroenterol Res Pract       Date:  2010-07-28       Impact factor: 2.260

9.  Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes.

Authors:  Y A Kesäniemi; T A Miettinen; M P Salaspuro
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

10.  Effect of cholestyramine on bile acid kinetics in patients with portal cirrhosis of the liver. Evidence of a selective defect in the formation of cholic acid.

Authors:  B Angelin; K Einarsson; K Hellstrom
Journal:  Am J Dig Dis       Date:  1978-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.